Literature DB >> 19135704

The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters.

Armando Tripodi1, Massimo Primignani, Veena Chantarangkul, Ylenia Viscardi, Alessandra Dell'Era, Federica M Fabris, Pier Mannuccio Mannucci.   

Abstract

BACKGROUND: Thromboelastometry allows continuous registration of the blood viscoelastic changes upon activation by cephaline or tissue-factor plus calcium-chloride. The technique is used as a near-patient-testing device to guide transfusion in cardiac surgery or liver transplantation and less to investigate hemostasis in acquired or congenital coagulopathies. AIMS: (i) Review of the coagulopathy associated with cirrhosis and (ii) report on its investigation by thromboelastometry in comparison with conventional coagulation parameters.
METHODS: We investigated citrated blood samples from 51 adult cirrhotics for the following thromboelastometry parameters: coagulation-time (CT), clot-formation-time (CFT), maximum-clot-firmness (MCF).
RESULTS: Relatively few patients [14/51(27%)] were identified as abnormal by CT; in contrast, a greater proportion were identified by the CFT [41/51(80%)] or MCF [39/51(76%)]. CFT and MCF were correlated with the platelet-count, antithrombin and fibrinogen. Prothrombin time (PT) was correlated with CFT and MCF. None of the coagulation parameters were correlated with CT. The correlation of the Child-Pugh-score (taken as index of severity) versus MCF or PT was -0.457(p < 0.001) or 0.484(p < 0.001), suggesting MCF as a suitable prognostic index. CFT and MCF, but not CT obtained ROC curves that were useful to distinguish patients from healthy individuals.
CONCLUSIONS: Thromboelastometry, currently used to assist liver transplantation is also suitable for investigating stable cirrhosis. CFT and MCF are the most interesting parameters to be considered for future clinical studies needed to assess their value as measures of bleeding-risk and prognosis in this category of patients.

Entities:  

Mesh:

Year:  2009        PMID: 19135704     DOI: 10.1016/j.thromres.2008.11.008

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  28 in total

1.  Thromboelastometry and Thrombelastography Analysis under Normal Physiological Conditions - Systematic Review.

Authors:  Marcel Adler; Sandra Ivic; Nicolas S Bodmer; Hugo Ten Cate; Lucas M Bachmann; Walter A Wuillemin; Michael Nagler
Journal:  Transfus Med Hemother       Date:  2017-03-08       Impact factor: 3.747

2.  Use of thromboelastography in the management of liver cirrhosis and accelerated intravascular coagulation and fibrinolysis (AICF).

Authors:  Thomas Joseph Peterson; Allison Margaret Brown Webb; Benjamin Samuel Vipler
Journal:  BMJ Case Rep       Date:  2016-12-14

3.  Fibrinogen measurement in liver disease: validation of the functional fibrinogen thromboelastography assay and a novel mathematical predictive model.

Authors:  Kirsty Rizzo; Kevin Vella; Daniel Zammit; Peter Gatt; Charlie Grima; Monique Borg Inguanez; Jurgen Gerada; Pierre Ellul; Mario Vassallo; Neville Azzopardi; James Pocock; Alex Gatt
Journal:  Blood Transfus       Date:  2018-11-09       Impact factor: 3.443

Review 4.  Coagulopathy in liver disease: Lack of an assessment tool.

Authors:  Annabel Blasi
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

5.  Bleeding and thrombotic complications of pediatric liver transplant.

Authors:  Alexandra J Borst; Debra L Sudan; Laura A Wang; Michael J Neuss; Jennifer A Rothman; Thomas L Ortel
Journal:  Pediatr Blood Cancer       Date:  2018-01-19       Impact factor: 3.167

6.  Thromboelastography Parameters Are Associated with Cirrhosis Severity.

Authors:  Ruhail Kohli; Alexandra Shingina; Stephen New; Shruti Chaturvedi; Alexander Benson; Scott W Biggins; Kiran Bambha
Journal:  Dig Dis Sci       Date:  2019-03-26       Impact factor: 3.199

7.  Preoperative Thromboelastometry as a Predictor of Transfusion Requirements during Adult Living Donor Liver Transplantation.

Authors:  Nirmeen Fayed; Wessam Mourad; Khaled Yassen; Klaus Görlinger
Journal:  Transfus Med Hemother       Date:  2015-03-31       Impact factor: 3.747

Review 8.  Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged.

Authors:  Armando Tripodi; Massimo Primignani; Pier Mannuccio Mannucci
Journal:  Intern Emerg Med       Date:  2009-08-28       Impact factor: 3.397

9.  Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy?

Authors:  Marco Senzolo; Maria Teresa Sartori; Ton Lisman
Journal:  HPB (Oxford)       Date:  2009-09       Impact factor: 3.647

10.  Thromboelastography for Assessing the Risk of Bleeding in Patients With Cirrhosis-Moving Closer.

Authors:  Vaibhav Somani; Deepak Amarapurkar; Apurva Shah
Journal:  J Clin Exp Hepatol       Date:  2017-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.